ConductScience.org, home

Paper32235331

Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine.

Montemagno C and 1 other. Cancers (Basel), 2020. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine. Papers, record 32235331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32235331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2020
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.4
iCite
Revised in PubMed
2020-09-28
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Montemagno CChristopherhttps://orcid.org/0000-0002-5687-1812
2Pagès GGilles

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References100

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121455667Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast.Breast Cancer Res Treat2012https://conductscience.org/library/papers/21455667PubMed
223237552On the origin of cancer metastasis.Crit Rev Oncog2013https://conductscience.org/library/papers/23237552PubMed
321207426Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ.Int J Cancer2011https://conductscience.org/library/papers/21207426PubMed
429752180[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.Lancet Oncol2018https://conductscience.org/library/papers/29752180PubMed
516826579Primary breast cancer phenotypes associated with propensity for central nervous system metastases.Cancer2006https://conductscience.org/library/papers/16826579PubMed
617957189Models, mechanisms and clinical evidence for cancer dormancy.Nat Rev Cancer2007https://conductscience.org/library/papers/17957189PubMed
727151988Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.J Nucl Med2016https://conductscience.org/library/papers/27151988PubMed
815992701New insights on cell death from radiation exposure.Lancet Oncol2005https://conductscience.org/library/papers/15992701PubMed
918026089Adaptive immunity maintains occult cancer in an equilibrium state.Nature2007https://conductscience.org/library/papers/18026089PubMed
1029042793Theranostics in nuclear medicine practice.Onco Targets Ther2017https://conductscience.org/library/papers/29042793PubMed
1126536664Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.Oncotarget2015https://conductscience.org/library/papers/26536664PubMed
122760978968Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.J Nucl Med2017https://conductscience.org/library/papers/27609789PubMed
1322711854Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.J Clin Oncol2012https://conductscience.org/library/papers/22711854PubMed
1426392755Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials.Drug Des Devel Ther2015https://conductscience.org/library/papers/26392755PubMed
152861896668Ga/177Lu-labeled DOTA-TATE shows similar imaging and biodistribution in neuroendocrine tumor model.Tumour Biol2017https://conductscience.org/library/papers/28618966PubMed
1617973263HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy.Int J Cancer2008https://conductscience.org/library/papers/17973263PubMed
1710684910Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.N Engl J Med2000https://conductscience.org/library/papers/10684910PubMed
1823487015Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.J Nucl Med2013https://conductscience.org/library/papers/23487015PubMed
1928613198Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry.Mol Imaging Radionucl Ther2017https://conductscience.org/library/papers/28613198PubMed
2012829800Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci U S A2003https://conductscience.org/library/papers/12829800PubMed

See all 100 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
41021173Deciphering key chemotherapeutic drug targets within tyrosine metabolism for breast cancer and advancing a wide-ranging diagnostic strategy.Discov Oncol2025https://conductscience.org/library/papers/41021173PubMed
37605516Histologic heterogeneity predicts patient prognosis of HER2-positive metastatic breast cancer: A retrospective study based on SEER database.Cancer Med2023https://conductscience.org/library/papers/37605516PubMed
35953532Pivotal models and biomarkers related to the prognosis of breast cancer based on the immune cell interaction network.Sci Rep2022https://conductscience.org/library/papers/35953532PubMed
35451558miR-450a exerts oncosuppressive effects in breast carcinoma by targeting CREB1.Kaohsiung J Med Sci2022https://conductscience.org/library/papers/35451558PubMed
34684834
Palmatine, a Bioactive Protoberberine Alkaloid Isolated from Berberis cretica, Inhibits the Growth of Human Estrogen Receptor-Positive Breast Cancer Cells and Acts Synergistically and Additively with Doxorubicin.
Molecules2021https://conductscience.org/library/papers/34684834PubMed
33925632Theranostic Advances in Breast Cancer in Nuclear Medicine.Int J Mol Sci2021https://conductscience.org/library/papers/33925632PubMed

Download CSV of cited by

Genes15

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32235331

GET https://conductscience.org/api/papers/v1/32235331/references?page=2